Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,889
archived clinical trials in
Blood Cancer

Elevate CLL R/R: Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia
A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase III Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia
Status: Enrolling
Updated:  12/14/2017
Clinical Research Facility
mi
from
Everett, WA
Elevate CLL R/R: Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia
A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase III Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia
Status: Enrolling
Updated: 12/14/2017
Clinical Research Facility
mi
from
Everett, WA
Click here to add this to my saved trials
Elevate CLL R/R: Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia
A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase III Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia
Status: Enrolling
Updated:  12/14/2017
Clinical Research Facility
mi
from
Seattle, WA
Elevate CLL R/R: Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia
A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase III Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia
Status: Enrolling
Updated: 12/14/2017
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Elevate CLL R/R: Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia
A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase III Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia
Status: Enrolling
Updated:  12/14/2017
Clinical Research Facility
mi
from
Spokane, WA
Elevate CLL R/R: Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia
A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase III Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia
Status: Enrolling
Updated: 12/14/2017
Clinical Research Facility
mi
from
Spokane, WA
Click here to add this to my saved trials
Elevate CLL R/R: Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia
A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase III Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia
Status: Enrolling
Updated:  12/14/2017
Clinical Research Facility
mi
from
Tacoma, WA
Elevate CLL R/R: Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia
A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase III Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia
Status: Enrolling
Updated: 12/14/2017
Clinical Research Facility
mi
from
Tacoma, WA
Click here to add this to my saved trials
Elevate CLL R/R: Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia
A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase III Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia
Status: Enrolling
Updated:  12/14/2017
mi
from
Darlinghurst,
Elevate CLL R/R: Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia
A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase III Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia
Status: Enrolling
Updated: 12/14/2017
mi
from
Darlinghurst,
Click here to add this to my saved trials
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients With Untreated AML 60-75 Years of Age.
Status: Enrolling
Updated:  12/15/2017
Arizona Cancer Center
mi
from
Tucson, AZ
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients With Untreated AML 60-75 Years of Age.
Status: Enrolling
Updated: 12/15/2017
Arizona Cancer Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients With Untreated AML 60-75 Years of Age.
Status: Enrolling
Updated:  12/15/2017
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients With Untreated AML 60-75 Years of Age.
Status: Enrolling
Updated: 12/15/2017
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients With Untreated AML 60-75 Years of Age.
Status: Enrolling
Updated:  12/15/2017
UC Davis Cancer Center
mi
from
Sacramento, CA
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients With Untreated AML 60-75 Years of Age.
Status: Enrolling
Updated: 12/15/2017
UC Davis Cancer Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients With Untreated AML 60-75 Years of Age.
Status: Enrolling
Updated:  12/15/2017
University of California Med. Center
mi
from
San Francisco, CA
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients With Untreated AML 60-75 Years of Age.
Status: Enrolling
Updated: 12/15/2017
University of California Med. Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients With Untreated AML 60-75 Years of Age.
Status: Enrolling
Updated:  12/15/2017
University of Colorado Cancer Center
mi
from
Aurora, CO
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients With Untreated AML 60-75 Years of Age.
Status: Enrolling
Updated: 12/15/2017
University of Colorado Cancer Center
mi
from
Aurora, CO
Click here to add this to my saved trials
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients With Untreated AML 60-75 Years of Age.
Status: Enrolling
Updated:  12/15/2017
Shands Jacksonville Medical Center
mi
from
Jacksonville, FL
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients With Untreated AML 60-75 Years of Age.
Status: Enrolling
Updated: 12/15/2017
Shands Jacksonville Medical Center
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients With Untreated AML 60-75 Years of Age.
Status: Enrolling
Updated:  12/15/2017
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients With Untreated AML 60-75 Years of Age.
Status: Enrolling
Updated: 12/15/2017
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients With Untreated AML 60-75 Years of Age.
Status: Enrolling
Updated:  12/15/2017
Blood and Marrow Transplant Group of Georgia
mi
from
Atlanta, GA
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients With Untreated AML 60-75 Years of Age.
Status: Enrolling
Updated: 12/15/2017
Blood and Marrow Transplant Group of Georgia
mi
from
Atlanta, GA
Click here to add this to my saved trials
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients With Untreated AML 60-75 Years of Age.
Status: Enrolling
Updated:  12/15/2017
Robert H.Lurie Comprehensive Cancer Center
mi
from
Chicago, IL
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients With Untreated AML 60-75 Years of Age.
Status: Enrolling
Updated: 12/15/2017
Robert H.Lurie Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients With Untreated AML 60-75 Years of Age.
Status: Enrolling
Updated:  12/15/2017
Rush University Medical Center
mi
from
Chicago, IL
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients With Untreated AML 60-75 Years of Age.
Status: Enrolling
Updated: 12/15/2017
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients With Untreated AML 60-75 Years of Age.
Status: Enrolling
Updated:  12/15/2017
St.Francis Hospital
mi
from
Beech Grove, IN
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients With Untreated AML 60-75 Years of Age.
Status: Enrolling
Updated: 12/15/2017
St.Francis Hospital
mi
from
Beech Grove, IN
Click here to add this to my saved trials
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients With Untreated AML 60-75 Years of Age.
Status: Enrolling
Updated:  12/15/2017
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients With Untreated AML 60-75 Years of Age.
Status: Enrolling
Updated: 12/15/2017
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients With Untreated AML 60-75 Years of Age.
Status: Enrolling
Updated:  12/15/2017
Northern New Jersey Cancer Associates
mi
from
Hackensack, NJ
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients With Untreated AML 60-75 Years of Age.
Status: Enrolling
Updated: 12/15/2017
Northern New Jersey Cancer Associates
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients With Untreated AML 60-75 Years of Age.
Status: Enrolling
Updated:  12/15/2017
North Shore University Hospital
mi
from
Manhasset, NY
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients With Untreated AML 60-75 Years of Age.
Status: Enrolling
Updated: 12/15/2017
North Shore University Hospital
mi
from
Manhasset, NY
Click here to add this to my saved trials
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients With Untreated AML 60-75 Years of Age.
Status: Enrolling
Updated:  12/15/2017
Weil Cornell Medical Center
mi
from
New York, NY
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients With Untreated AML 60-75 Years of Age.
Status: Enrolling
Updated: 12/15/2017
Weil Cornell Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients With Untreated AML 60-75 Years of Age.
Status: Enrolling
Updated:  12/15/2017
New York Medical College, Division of Oncology
mi
from
Valhalla, NY
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients With Untreated AML 60-75 Years of Age.
Status: Enrolling
Updated: 12/15/2017
New York Medical College, Division of Oncology
mi
from
Valhalla, NY
Click here to add this to my saved trials
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients With Untreated AML 60-75 Years of Age.
Status: Enrolling
Updated:  12/15/2017
Blumenthal Cancer Center/Mecklenburg Medical Group
mi
from
Charlotte, NC
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients With Untreated AML 60-75 Years of Age.
Status: Enrolling
Updated: 12/15/2017
Blumenthal Cancer Center/Mecklenburg Medical Group
mi
from
Charlotte, NC
Click here to add this to my saved trials
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients With Untreated AML 60-75 Years of Age.
Status: Enrolling
Updated:  12/15/2017
Jewish Hospital
mi
from
Cincinnati, OH
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients With Untreated AML 60-75 Years of Age.
Status: Enrolling
Updated: 12/15/2017
Jewish Hospital
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients With Untreated AML 60-75 Years of Age.
Status: Enrolling
Updated:  12/15/2017
Oregon Health and Science University
mi
from
Portland, OR
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients With Untreated AML 60-75 Years of Age.
Status: Enrolling
Updated: 12/15/2017
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients With Untreated AML 60-75 Years of Age.
Status: Enrolling
Updated:  12/15/2017
M.D. Anderson Cancer Center
mi
from
Houston, TX
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients With Untreated AML 60-75 Years of Age.
Status: Enrolling
Updated: 12/15/2017
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients With Untreated AML 60-75 Years of Age.
Status: Enrolling
Updated:  12/15/2017
Joe Arrington Cancer Center
mi
from
Lubbock, TX
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients With Untreated AML 60-75 Years of Age.
Status: Enrolling
Updated: 12/15/2017
Joe Arrington Cancer Center
mi
from
Lubbock, TX
Click here to add this to my saved trials
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients With Untreated AML 60-75 Years of Age.
Status: Enrolling
Updated:  12/15/2017
Texas Tech University Health Sciences Center
mi
from
Lubbock, TX
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients With Untreated AML 60-75 Years of Age.
Status: Enrolling
Updated: 12/15/2017
Texas Tech University Health Sciences Center
mi
from
Lubbock, TX
Click here to add this to my saved trials
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients With Untreated AML 60-75 Years of Age.
Status: Enrolling
Updated:  12/15/2017
Cancer Therapy and Research Center at the University of Texas
mi
from
San Antonio, TX
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients With Untreated AML 60-75 Years of Age.
Status: Enrolling
Updated: 12/15/2017
Cancer Therapy and Research Center at the University of Texas
mi
from
San Antonio, TX
Click here to add this to my saved trials
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients With Untreated AML 60-75 Years of Age.
Status: Enrolling
Updated:  12/15/2017
Froedlert Hospital/Medical College of Wisconsin
mi
from
Milwaukee, WI
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients With Untreated AML 60-75 Years of Age.
Status: Enrolling
Updated: 12/15/2017
Froedlert Hospital/Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients With Untreated AML 60-75 Years of Age.
Status: Enrolling
Updated:  12/15/2017
BC Cancer Research Center
mi
from
Vancouver,
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients With Untreated AML 60-75 Years of Age.
Status: Enrolling
Updated: 12/15/2017
BC Cancer Research Center
mi
from
Vancouver,
Click here to add this to my saved trials
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients With Untreated AML 60-75 Years of Age.
Status: Enrolling
Updated:  12/15/2017
University of Pittsburg Cancer Center
mi
from
Pittsburgh, PA
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients With Untreated AML 60-75 Years of Age.
Status: Enrolling
Updated: 12/15/2017
University of Pittsburg Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Phase Ib Study of Nivolumab and Dasatinib in Patients With Relapsed/Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Status: Enrolling
Updated:  12/19/2017
Northwestern University
mi
from
Chicago, IL
Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Phase Ib Study of Nivolumab and Dasatinib in Patients With Relapsed/Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Status: Enrolling
Updated: 12/19/2017
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Human Placental-Derived Stem Cell Transplantation
A Single-Arm Study to Assess the Safety of Transplantation With Human Placental-Derived Stem-Cells Combined With Unrelated and Related Cord Blood in Subjects With Certain Malignant Hematologic Diseases and Non-Malignant Disorders
Status: Enrolling
Updated:  12/20/2017
New York Medical College
mi
from
Valhalla, NY
Human Placental-Derived Stem Cell Transplantation
A Single-Arm Study to Assess the Safety of Transplantation With Human Placental-Derived Stem-Cells Combined With Unrelated and Related Cord Blood in Subjects With Certain Malignant Hematologic Diseases and Non-Malignant Disorders
Status: Enrolling
Updated: 12/20/2017
New York Medical College
mi
from
Valhalla, NY
Click here to add this to my saved trials
Human Placental-Derived Stem Cell Transplantation
A Single-Arm Study to Assess the Safety of Transplantation With Human Placental-Derived Stem-Cells Combined With Unrelated and Related Cord Blood in Subjects With Certain Malignant Hematologic Diseases and Non-Malignant Disorders
Status: Enrolling
Updated:  12/20/2017
University of Utah
mi
from
Salt Lake City, UT
Human Placental-Derived Stem Cell Transplantation
A Single-Arm Study to Assess the Safety of Transplantation With Human Placental-Derived Stem-Cells Combined With Unrelated and Related Cord Blood in Subjects With Certain Malignant Hematologic Diseases and Non-Malignant Disorders
Status: Enrolling
Updated: 12/20/2017
University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Human Placental-Derived Stem Cell Transplantation
A Single-Arm Study to Assess the Safety of Transplantation With Human Placental-Derived Stem-Cells Combined With Unrelated and Related Cord Blood in Subjects With Certain Malignant Hematologic Diseases and Non-Malignant Disorders
Status: Enrolling
Updated:  12/20/2017
Childrens Hospital Colorado
mi
from
Denver, CO
Human Placental-Derived Stem Cell Transplantation
A Single-Arm Study to Assess the Safety of Transplantation With Human Placental-Derived Stem-Cells Combined With Unrelated and Related Cord Blood in Subjects With Certain Malignant Hematologic Diseases and Non-Malignant Disorders
Status: Enrolling
Updated: 12/20/2017
Childrens Hospital Colorado
mi
from
Denver, CO
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Sutter Cancer Center at Roseville Medical Center
mi
from
Roseville, CA
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Sutter Cancer Center at Roseville Medical Center
mi
from
Roseville, CA
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Sutter Cancer Center
mi
from
Sacramento, CA
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Sutter Cancer Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center
mi
from
Hartford, CT
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center
mi
from
Hartford, CT
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Tunnell Cancer Center at Beebe Medical Center
mi
from
Lewes, DE
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Tunnell Cancer Center at Beebe Medical Center
mi
from
Lewes, DE
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
CCOP - Christiana Care Health Services
mi
from
Newark, DE
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
CCOP - Christiana Care Health Services
mi
from
Newark, DE
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
M.D. Anderson Cancer Center at Orlando
mi
from
Orlando, FL
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
M.D. Anderson Cancer Center at Orlando
mi
from
Orlando, FL
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
H. Lee Moffitt Cancer Center and Research Institute at University of South Florida
mi
from
Tampa, FL
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
H. Lee Moffitt Cancer Center and Research Institute at University of South Florida
mi
from
Tampa, FL
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center
mi
from
Boise, ID
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center
mi
from
Boise, ID
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
mi
from
Chicago, IL
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Hematology and Oncology Associates
mi
from
Chicago, IL
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Hematology and Oncology Associates
mi
from
Chicago, IL
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Kellogg Cancer Care Center
mi
from
Highland Park, IL
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Kellogg Cancer Care Center
mi
from
Highland Park, IL
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Provena St. Mary's Regional Cancer Center - Kankakee
mi
from
Kankakee, IL
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Provena St. Mary's Regional Cancer Center - Kankakee
mi
from
Kankakee, IL
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
North Shore Oncology and Hematology Associates, Limited - Libertyville
mi
from
Libertyville, IL
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
North Shore Oncology and Hematology Associates, Limited - Libertyville
mi
from
Libertyville, IL
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Cardinal Bernardin Cancer Center at Loyola University Medical Center
mi
from
Maywood, IL
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Cardinal Bernardin Cancer Center at Loyola University Medical Center
mi
from
Maywood, IL
Click here to add this to my saved trials
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  12/21/2017
Cancer Care and Hematology Specialists of Chicagoland - Niles
mi
from
Niles, IL
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 12/21/2017
Cancer Care and Hematology Specialists of Chicagoland - Niles
mi
from
Niles, IL
Click here to add this to my saved trials